ObesityPhase 3NCT07654361
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
A Phase 3 study testing Aleniglipron in people with Obesity and Overweight, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics at 71 sites in United States.
Trial summary
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and… Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Obesity, Overweight, Chronic Weight Management
- What is being tested?
- Aleniglipron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3,600 participants
- Where
- 71 sitesUnited States
- Study dates
- 13 Jul 2026to Nov 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent
- BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.
Who cannot join
- Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
- Self-reported change in body weight >5 kg within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
- Have or plan to have endoscopic and/or device-based therapy for obesity.
- Have obesity induced by other endocrine disorders.
- Impaired renal function at Screening
- Chronic malabsorption
Trial locations and contacts
71 sites in 1 country. Contact the study team or a site near you to ask about taking part.
71 sites in 1 country
United States71 sites, 71 recruiting
- Not yet recruiting
ACCOMPLISH-1 Research Site
Albany, New York, 12208-3473
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Ann Arbor, Michigan, 48105-1912
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Austin, Texas, 78704
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Austin, Texas, 78731
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Baton Rouge, Louisiana, 70808
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Birmingham, Alabama, 35242
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Birmingham, Alabama, 35294-3360
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Brooklyn, New York, 11220
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Buford, Georgia, 30046
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Butte, Montana, 59701
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Charlotte, North Carolina, 28210
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Chesterfield, Missouri, 63005
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Chicago, Illinois, 60637
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Clearwater, Florida, 33756
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Columbus, Georgia, 31904
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Columbus, Ohio, 43213
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Columbus, Ohio, 43215
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Denison, Texas, 75020-4582
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Durham, North Carolina, 27710-3000
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Escondido, California, 92025
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Fayetteville, North Carolina, 28304
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Gardena, California, 92708
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Greer, South Carolina, 29651
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Gulfport, Mississippi, 39503
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Hazelwood, Missouri, 63042
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Honolulu, Hawaii, 96814-4526
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Houston, Texas, 77040
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Houston, Texas, 77054
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Iowa City, Iowa, 52242
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Knoxville, Tennessee, 37920
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
La Jolla, California, 92108
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Las Vegas, Nevada, 89128
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Lawrenceville, Georgia, 30046
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Leesburg, Florida, 34748
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Louisville, Kentucky, 40213
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Mankato, Minnesota, 56001
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Meridian, Idaho, 83646
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Methuen, Massachusetts, 01844
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Miami, Florida, 33136
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Missoula, Montana, 59804
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Modesto, California, 95355
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Moore, Oklahoma, 73160
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Needham, Massachusetts, 02492
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
New Bern, North Carolina, 28562
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Ocala, Florida, 34470
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Ocoee, Florida, 34761
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Omaha, Nebraska, 68198-7400
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Pembroke, Florida, 33027
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Philadelphia, Pennsylvania, 19152
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Phoenix, Arizona, 85225
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Portland, Oregon, 97202
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Renton, Washington, 98057
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Rexburg, Idaho, 83440
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Richfield, Minnesota, 55423
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Ridgeland, Mississippi, 39157
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Rolling Hills Estates, California, 90274
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
San Antonio, Texas, 78231
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
San Diego, California, 92123
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Sandy City, Utah, 84094
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Silver Spring, Maryland, 20901-4402
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
St Louis, Missouri, 63303-3041
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
St. George, Utah, 84790
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Sun City West, Arizona, 85375
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Tampa, Florida, 33617
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Tucson, Arizona, 85741
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Union City, Georgia, 30291
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Wichita, Kansas, 67218
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-1 Research Site
Wilmington, North Carolina, 28401
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Winston-Salem, North Carolina, 27104
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Woodstock, Georgia, 30189
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-1 Research Site
Wylie, Texas, 75098
Medical Director, GSBRClinicalTrials@structuretx.com
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Being tested
- Aleniglipron, Placebo
- Keywords
- Obesity, Overweight, GSBR-1290, Aleniglipron, Chronic weight management, Obese, Small molecule, GLP-1, Structure Therapeutics
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AleniglipronDrug
Drug: aleniglipron administered orally Drug
PlaceboDrug
Drug: placebo administered orally
| Study group | Role | What they receive |
|---|---|---|
| aleniglipron Arm 1 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: Aleniglipron |
| aleniglipron Arm 2 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: Aleniglipron |
| aleniglipron Arm 3 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: Aleniglipron |
| Placebo Arm 4 | Experimental | Participants will receive placebo administered orally. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change in body weight from Baseline
Measured: Baseline and Week 76
Secondary outcomes (14)
Change in body weight (absolute) from Baseline
Measured: Baseline and week 76
Percentage of participants who achieve ≥5% reduction in body weight
Measured: Baseline and week 76
Percentage of participants who achieve ≥10% reduction in body weight
Measured: Baseline and week 76
Percentage of participants who achieve ≥15% reduction in body weight
Measured: Baseline and week 76
Percentage of participants who achieve ≥20% reduction in body weight
Measured: Baseline and week 76
Change in waist circumference from Baseline
Measured: Baseline and week 76
Change in resting systolic blood pressure from Baseline
Measured: Baseline and week 76
Percent change in fasting triglycerides and non-HDL cholesterol from Baseline
Measured: Baseline and week 76
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version physical function from Baseline
Measured: Baseline and week 76
Change in HbA1c from Baseline
Measured: Baseline and week 76
Change in body mass index from Baseline
Measured: Baseline and week 76
Percent change in fasting total cholesterol from Baseline
Measured: Baseline and week 76
Change in fasting glucose from Baseline
Measured: Baseline and week 76
Change in resting diastolic blood pressure from Baseline
Measured: Baseline and week 76
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start13 Jul 2026
- Primary completionSep 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 3,600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07654361
- Sponsor's protocol ID
- GSBR-1290-12
- Status last verified
- Jun 2026
- First submitted
- 12 Jun 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
- ClinicalTrials.gov ID
- NCT07654361
- Acronym / sponsor ID
- GSBR-1290-12
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Keywords
- Obesity, Overweight, GSBR-1290, Aleniglipron, Chronic weight management, Obese, Small molecule, GLP-1
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3,600 participants (estimated)
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 13 Jul 2026 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| aleniglipron Arm 1 | Experimental | Drug: AleniglipronParticipants will receive aleniglipron administered orally. |
| aleniglipron Arm 2 | Experimental | Drug: AleniglipronParticipants will receive aleniglipron administered orally. |
| aleniglipron Arm 3 | Experimental | Drug: AleniglipronParticipants will receive aleniglipron administered orally. |
| Placebo Arm 4 | Experimental | Drug: PlaceboParticipants will receive placebo administered orally. |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Signed informed consent
- BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.
Key exclusion criteria (7 listed)
- Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
- Self-reported change in body weight >5 kg within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
- Have or plan to have endoscopic and/or device-based therapy for obesity.
- Have obesity induced by other endocrine disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AleniglipronDrug: aleniglipron administered orally Drug | Drug | aleniglipron Arm 1, aleniglipron Arm 2, aleniglipron Arm 3 |
| PlaceboDrug: placebo administered orally | Drug | Placebo Arm 4 |
Primary outcome
Percent change in body weight from Baseline
Time frame: Baseline and Week 76
14 secondary outcomes
Change in body weight (absolute) from Baseline
Time frame: Baseline and week 76
Percentage of participants who achieve ≥5% reduction in body weight
Time frame: Baseline and week 76
Percentage of participants who achieve ≥10% reduction in body weight
Time frame: Baseline and week 76
Percentage of participants who achieve ≥15% reduction in body weight
Time frame: Baseline and week 76
Percentage of participants who achieve ≥20% reduction in body weight
Time frame: Baseline and week 76
Change in waist circumference from Baseline
Time frame: Baseline and week 76
Change in resting systolic blood pressure from Baseline
Time frame: Baseline and week 76
Percent change in fasting triglycerides and non-HDL cholesterol from Baseline
Time frame: Baseline and week 76
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version physical function from Baseline
Time frame: Baseline and week 76
Change in HbA1c from Baseline
Time frame: Baseline and week 76
Change in body mass index from Baseline
Time frame: Baseline and week 76
Percent change in fasting total cholesterol from Baseline
Time frame: Baseline and week 76
Change in fasting glucose from Baseline
Time frame: Baseline and week 76
Change in resting diastolic blood pressure from Baseline
Time frame: Baseline and week 76
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
71 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Aleniglipron in people with Obesity and Overweight, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics at 71 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 71 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Medical Director (1-650-457-1959, GSBRClinicalTrials@structuretx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change in body weight from Baseline (time frame: Baseline and Week 76). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.